Mark Vignola compensation by year
Terns Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $416,300 | $445,000 | $475,000 |
| Bonus | $0 | $316,850 | $810,417 |
| Stock awards | $0 | $0 | $375,375 |
| Option awards | $225,640 | $2,162,872 | $528,120 |
| Non-equity incentive | $249,780 | $195,800 | $190,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $16,610 | $16,510 | $538,025 |
| Total | $908,330 | $3,137,032 | $2,916,937 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Terns Pharmaceuticals, Inc. DEF 14A filed January 1, 1900, accession 0000950170-25-060138, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Terns Pharmaceuticals, Inc. filed document, accession 0000950170-25-060138. Every figure is read from that document and cited to the page and table it appears in. Filed January 1, 1900.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 68,750 | $380,875 | — |
| Option | 17,605 | — | $5.36 |
| Option | 187,500 | — | $8.94 |
| Option | 137,500 | — | $5.46 |
| Option | 22,500 | — | $10.72 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Terns Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2024 proxy (filed January 1, 1900)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-01-06 | Sale | 10b5-1 | 9,059 | $5.80 | 74,752 |
| 2025-01-02 | Sale | 10b5-1 | 8,129 | $5.72 | 83,811 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Terns Pharmaceuticals’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Amy Burroughs | Chief Executive Officer and Director | $8,240,502 |
| Mark Vignola · this page | Former Chief Financial Officer and Treasurer | $2,916,937 |
| Melita Sun Jung | Chief Business Officer | $2,196,084 |
| Erin Quirk | Former President, Head of Research & Development | $1,934,963 |
Mark Vignola's compensation dossier, Terns Pharmaceuticals
You have read Mark Vignola's totals and holdings. The dossier adds each equity grant Terns Pharmaceuticals disclosed for Mark Vignola and Terns Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Terns Pharmaceuticals compensation record
free company briefThis page is one person within Terns Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Terns Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Terns Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TERN
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.